NeuroPace has reported the initial primary endpoint one-year outcomes from the NAUTILUS trial of the RNS System.

SAGA Diagnostics has commercially launched the multi-cancer molecular residual disease (MRD) platform, Pathlight, in the US.

The CEO of Flow Neuroscience has called out the US Food and Drug Administration (FDA) for market entry delays for clinically ...

The US Food and Drug Administration (FDA) has granted approval for Abbott's Tendyne transcatheter mitral valve replacement ...

Danish medtech Brainreader has secured $7.3m (€6.6m) to support the market rollout of Neuroreader, its artificial ...